Bosutinib

Bosutinib
Systematic (IUPAC) name
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 380843-75-4 Y
ATC code L01XE14
PubChem CID 5328940
UNII 5018V4AEZ0 Y
ChEMBL CHEMBL288441 Y
Chemical data
Formula C26H29Cl2N5O3 
Mol. mass 530.446 g/mol
 Y(what is this?)  (verify)

Bosutinib (rINN/USAN; codenamed SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.[1]

It is being developed by Pfizer.

See also

References

  1. ^ Vultur A, Buettner R, Kowolik C, et al. (May 2008). "SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells". Mol. Cancer Ther. 7 (5): 1185–94. doi:10.1158/1535-7163.MCT-08-0126. PMC 2794837. PMID 18483306. http://mct.aacrjournals.org/cgi/pmidlookup?view=long&pmid=18483306. 

External links

CI monoclonal antibodies ("-mab")
Others for solid tumors
Tyrosine-kinase inhibitors ("-nib")
Other

M: NEO

tsoc, mrkr

tumr, epon, para

drug (L1i/1e/V03)